In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
A new study has found that Mounjaro may not only be good at treating diabetes, but could actually help prevent the disease.
The 503A facilities are also producing compounded semaglutide and tirzepatide for hundreds of thousands of patients.
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?
The recent success of drug therapies such as semaglutide and tirzepatide has fueled obesity research. In a phase 2 trial that enrolled patients with type 2 diabetes (ClinicalTrials.gov Identifier: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback